Satsuma Pharmaceuticals Top Management

STSADelisted Stock  USD 1.10  0.01  0.90%   
Satsuma Pharmaceuticals employs about 25 people. The company is managed by 7 executives with a total tenure of roughly 59 years, averaging almost 8.0 years of service per executive, having 3.57 employees per reported executive. Analysis of Satsuma Pharmaceuticals' management performance can provide insight into the company performance.
  
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

Satsuma Pharmaceuticals Management Team Effectiveness

The company has return on total asset (ROA) of (0.4962) % which means that it has lost $0.4962 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0404) %, meaning that it created substantial loss on money invested by shareholders. Satsuma Pharmaceuticals' management efficiency ratios could be used to measure how well Satsuma Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.

Satsuma Pharmaceuticals Workforce Comparison

Satsuma Pharmaceuticals is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 1,166. Satsuma Pharmaceuticals holds roughly 25.0 in number of employees claiming about 2.14% of equities under Health Care industry.

Satsuma Pharmaceuticals Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Satsuma Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Satsuma Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Satsuma Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Satsuma Pharmaceuticals Notable Stakeholders

A Satsuma Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Satsuma Pharmaceuticals often face trade-offs trying to please all of them. Satsuma Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Satsuma Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Robert SchultzManufacturing ChemistryProfile
Robert JanoskyChief OfficerProfile
John MBACEO PresProfile
Detlef AlbrechtChief OfficerProfile
Mic IwashimaVP OperationsProfile
Thomas ONeilChief OfficerProfile
Shannon StromVP AffairsProfile

About Satsuma Pharmaceuticals Management Performance

The success or failure of an entity such as Satsuma Pharmaceuticals often depends on how effective the management is. Satsuma Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Satsuma management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Satsuma management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California. Satsuma Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 25 people.
Please note, the presentation of Satsuma Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Satsuma Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Satsuma Pharmaceuticals' management manipulating its earnings.

Satsuma Pharmaceuticals Workforce Analysis

Traditionally, organizations such as Satsuma Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Satsuma Pharmaceuticals within its industry.

Satsuma Pharmaceuticals Manpower Efficiency

Return on Satsuma Pharmaceuticals Manpower

Revenue Per Employee0.0
Revenue Per Executive0.0
Net Loss Per Employee2.8M
Net Loss Per Executive10M
Working Capital Per Employee1.9M
Working Capital Per Executive6.7M
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.

Other Consideration for investing in Satsuma Stock

If you are still planning to invest in Satsuma Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Satsuma Pharmaceuticals' history and understand the potential risks before investing.
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.